Technology
Health
Biotechnology

Cidara

$1.89
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (0.53%) Today
-$0.02 (-1.05%) After Hours

Why Robinhood?

You can buy or sell Cidara and other stocks, options, ETFs, and crypto commission-free!

About

Cidara Therapeutics, Inc. Common Stock, also called Cidara, is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Read More Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Employees
68
Headquarters
San Diego, California
Founded
2012
Market Cap
51.15M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
108.54K
High Today
$1.94
Low Today
$1.87
Open Price
$1.92
Volume
62.97K
52 Week High
$6.35
52 Week Low
$1.85

Collections

Technology
Health
Biotechnology
Therapy
2015 IPO
US
North America

News

Yahoo FinanceMay 9

Cidara Provides Corporate Update and Reports First Quarter 2019 Financial Results

SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2019 and provided an update on its corporate activities and product pipeline. "Cidara made significant progress to begin 2019 by continuing to enroll patients in and advance our global Phase 3 ReSTORE trial of rezafungin for the treatment of patients with candidemia and invasi...

48

Earnings

-$0.94
-$0.77
-$0.61
-$0.44
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.